Mealey's (June 25, 2020, 8:34 AM EDT) -- NEW YORK — A federal judge in New York on June 23 ruled that lead plaintiffs in a securities class action lawsuit stemming from alleged misrepresentations made in the proxy materials for a merger deal between two biopharmaceutical companies that develop cancer treatment drugs have failed to plead any material misrepresentations or omissions or loss causation in making their federal securities law claims (In re GTx Shareholders Litigation, No. 19-3239, S.D. N.Y., 2020 U.S. Dist. LEXIS 109680)....